After a Serious Setback, Is Verve Therapeutics a Buy? [Yahoo! Finance]
Verve Therapeutics, Inc. (VERV)
Company Research
Source: Yahoo! Finance
Understandably, investors may now question whether the gene-editing biotech has a shot at recovering, or if it's doomed. Let's consider what happened in a bit more depth while doing our best to remain impartial regarding the stock's movement. This big red flag can't be ignored Verve's lead program -- called VERVE-101 -- is a gene-editing therapy that's intended to permanently treat or potentially even cure heterozygous familial hypercholesterolemia (HeFH), a hereditary disease that causes dangerously and chronically high levels of LDL-C cholesterol. In the long run, if it is shown to safely work for HeFH, VERVE-101 could be used to treat a wider population of people with atherosclerotic cardiovascular disease (ASCVD), which affects tens of millions of people in the U.S. and beyond. But, as you may have guessed, things are not going as planned. Per the company's data update, in VERVE-101's phase 1b clinical trial with 13 patients, one patient experienced a serious adverse event (
Show less
Read more
Impact Snapshot
Event Time:
VERV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VERV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VERV alerts
High impacting Verve Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VERV
News
- Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102GlobeNewswire
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
- Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
- Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAccesswire
VERV
Earnings
- 11/7/23 - Beat
VERV
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- VERV's page on the SEC website